<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323801</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001055</org_study_id>
    <secondary_id>K24HD082231</secondary_id>
    <nct_id>NCT03323801</nct_id>
  </id_info>
  <brief_title>RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia</brief_title>
  <official_title>A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Azoospermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Men with infertility and normal hormone levels have few options for fertility treatment.&#xD;
      Previous research suggests that men with infertility may have low levels of the active form&#xD;
      of Vitamin A, called retinoic acid, in their testes. In a pilot study of 20 men with low&#xD;
      numbers of sperm (&lt;10 million motile sperm), roughly half the men showed improvement in sperm&#xD;
      production. Thus, we want to see if retinoic acid administration to men with azoospermia (no&#xD;
      sperm present) can initiate sperm production.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty men with infertility, aged 21 - 60, due to azoospermia (no apparent sperm in the&#xD;
      ejaculate on two separate occasions) will be enrolled in a single-arm pilot trial of daily&#xD;
      oral therapy of 20 mg twice daily of 13-cis retinoic acid for 32 weeks. The impact of&#xD;
      treatment on the appearance of sperm in the ejaculate will be determined by monthly semen&#xD;
      analyses.&#xD;
&#xD;
      Note: The outcome measure of serum and seminal plasma 13-cis-retinoic acid concentrations was&#xD;
      entered in error and not intended to be reported for this study. Information on these levels&#xD;
      is available in our earlier study of 13-cis-retinoic acid in men with sub-fertility. Amory et&#xD;
      al. Andrology 2017 5:1115-1123.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>20 mg 13-cis retinoic acid twice daily (BID) with meals for 32 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Motile Sperm</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Number of participants with undetectable or detectable sperm in their ejaculates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Sperm and Percentage of These Sperm That Were Motile</measure>
    <time_frame>32 weeks</time_frame>
    <description>Number of total sperm in ejaculate and percentage of these sperm that were motile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious and Non-Serious Adverse Effects</measure>
    <time_frame>32 weeks</time_frame>
    <description>Number of participants with Serious and Non-Serious Adverse effects associated with treatment with 13-cis retinoic acid</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Male Infertility, Azoospermia</condition>
  <arm_group>
    <arm_group_label>13-cis retinoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13-cis retinoic acid</intervention_name>
    <description>Accutane is used for the treatment of severe acne</description>
    <arm_group_label>13-cis retinoic acid</arm_group_label>
    <other_name>Accutane, Isotretinoin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Infertile men with azoospermia on at least two semen analyses separated&#xD;
        by at least one week, and no pregnancy with partner with normal cycles and normal&#xD;
        hysterosalpingogram despite &gt;1 year of unprotected intercourse.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria: hypogonadotropic hypogonadism (that might respond to gonadotropin&#xD;
        injections); use of anabolic steroids,illicit drugs, or consumption of more than 4&#xD;
        alcoholic beverages daily; current therapy with retinoic acid (eg Accutane) or vitamin A-&#xD;
        of use of isotretinoin within eight weeks of start of dosing;phenytoin, or medication&#xD;
        containing tetracycline; personal history of serious psychiatric disorders, score of&#xD;
        greater than 15 on the PHQ9 (mood) questionnaire; elevated serum serum triglycerides or&#xD;
        other abnormal serum chemistry values; history of inflammatory bowel disease or bone&#xD;
        disease; not living within catchment area; participation in another clinical trial&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K Amory, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cdc.gov/nchs/fastats/fertile.htm</url>
    <description>Center for Disease Control, Infertility Facts, on June 3rd, 2013</description>
  </link>
  <reference>
    <citation>Jequier AM, Holmes SC. Primary testicular disease presenting as azoospermia or oligozoospermia in an infertility clinic. Br J Urol. 1993 Jun;71(6):731-5.</citation>
    <PMID>8102079</PMID>
  </reference>
  <reference>
    <citation>de Kretser DM. Male infertility. Lancet. 1997 Mar 15;349(9054):787-90. Review.</citation>
    <PMID>9074589</PMID>
  </reference>
  <reference>
    <citation>Schlegel PN. Nonobstructive azoospermia: a revolutionary surgical approach and results. Semin Reprod Med. 2009 Mar;27(2):165-70. doi: 10.1055/s-0029-1202305. Epub 2009 Feb 26. Review.</citation>
    <PMID>19247918</PMID>
  </reference>
  <reference>
    <citation>Napoli JL. Retinoic acid: its biosynthesis and metabolism. Prog Nucleic Acid Res Mol Biol. 1999;63:139-88. Review.</citation>
    <PMID>10506831</PMID>
  </reference>
  <reference>
    <citation>Doyle TJ, Braun KW, McLean DJ, Wright RW, Griswold MD, Kim KH. Potential functions of retinoic acid receptor A in Sertoli cells and germ cells during spermatogenesis. Ann N Y Acad Sci. 2007 Dec;1120:114-30. Epub 2007 Sep 28.</citation>
    <PMID>17905941</PMID>
  </reference>
  <reference>
    <citation>Koubova J, Menke DB, Zhou Q, Capel B, Griswold MD, Page DC. Retinoic acid regulates sex-specific timing of meiotic initiation in mice. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2474-9. Epub 2006 Feb 6.</citation>
    <PMID>16461896</PMID>
  </reference>
  <reference>
    <citation>Anderson EL, Baltus AE, Roepers-Gajadien HL, Hassold TJ, de Rooij DG, van Pelt AM, Page DC. Stra8 and its inducer, retinoic acid, regulate meiotic initiation in both spermatogenesis and oogenesis in mice. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14976-80. doi: 10.1073/pnas.0807297105. Epub 2008 Sep 17.</citation>
    <PMID>18799751</PMID>
  </reference>
  <reference>
    <citation>Chung SS, Wang X, Wolgemuth DJ. Expression of retinoic acid receptor alpha in the germline is essential for proper cellular association and spermiogenesis during spermatogenesis. Development. 2009 Jun;136(12):2091-100. doi: 10.1242/dev.020040.</citation>
    <PMID>19465599</PMID>
  </reference>
  <reference>
    <citation>Dufour JM, Kim KH. Cellular and subcellular localization of six retinoid receptors in rat testis during postnatal development: identification of potential heterodimeric receptors. Biol Reprod. 1999 Nov;61(5):1300-8.</citation>
    <PMID>10529278</PMID>
  </reference>
  <reference>
    <citation>Lohnes D, Kastner P, Dierich A, Mark M, LeMeur M, Chambon P. Function of retinoic acid receptor gamma in the mouse. Cell. 1993 May 21;73(4):643-58.</citation>
    <PMID>8388780</PMID>
  </reference>
  <reference>
    <citation>Lufkin T, Lohnes D, Mark M, Dierich A, Gorry P, Gaub MP, LeMeur M, Chambon P. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7225-9.</citation>
    <PMID>8394014</PMID>
  </reference>
  <reference>
    <citation>Ghyselinck NB, Vernet N, Dennefeld C, Giese N, Nau H, Chambon P, Viville S, Mark M. Retinoids and spermatogenesis: lessons from mutant mice lacking the plasma retinol binding protein. Dev Dyn. 2006 Jun;235(6):1608-22.</citation>
    <PMID>16586441</PMID>
  </reference>
  <reference>
    <citation>Hoting VE, Schütte B, Schirren C. [Isotretinoin treatment of acne conglobata. Andrologic follow-up]. Fortschr Med. 1992 Aug 20;110(23):427-30. German.</citation>
    <PMID>1398387</PMID>
  </reference>
  <reference>
    <citation>Vogt HJ, Ewers R. [13-cis-Retinoic acid and spermatogenesis. Spermatological and impulse cytophotometric studies]. Hautarzt. 1985 May;36(5):281-6. German.</citation>
    <PMID>3159708</PMID>
  </reference>
  <reference>
    <citation>Török L, Kádár L, Kása M. Spermatological investigations in patients treated with etretinate and isotretinoin. Andrologia. 1987 Nov-Dec;19(6):629-33.</citation>
    <PMID>3481225</PMID>
  </reference>
  <reference>
    <citation>Nya-Ngatchou JJ, Arnold SL, Walsh TJ, Muller CH, Page ST, Isoherranen N, Amory JK. Intratesticular 13-cis retinoic acid is lower in men with abnormal semen analyses: a pilot study. Andrology. 2013 Mar;1(2):325-31. doi: 10.1111/j.2047-2927.2012.00033.x. Epub 2012 Nov 29.</citation>
    <PMID>23413144</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <results_first_submitted>April 26, 2021</results_first_submitted>
  <results_first_submitted_qc>September 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2021</results_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>John Amory</investigator_full_name>
    <investigator_title>Professor, School of Medicine, General Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
    <mesh_term>Azoospermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03323801/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03323801/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13-cis Retinoic Acid</title>
          <description>20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks&#xD;
13-cis retinoic acid: Accutane is used for the treatment of severe acne</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Men with infertility due to azoospermia</population>
      <group_list>
        <group group_id="B1">
          <title>13-cis Retinoic Acid</title>
          <description>20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks&#xD;
13-cis retinoic acid: Accutane is used for the treatment of severe acne</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="31" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Motile Sperm</title>
        <description>Number of participants with undetectable or detectable sperm in their ejaculates.</description>
        <time_frame>up to 32 weeks</time_frame>
        <population>Men had idiopathic azoospermia, without evidence of obstruction or know genetic causes of azoospermia, although one man had known AZFc deletion</population>
        <group_list>
          <group group_id="O1">
            <title>Accutane-13-cis Retinoic Acid</title>
            <description>20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks&#xD;
13-cis retinoic acid: Accutane is used for the treatment of severe acne</description>
          </group>
        </group_list>
        <measure>
          <title>Total Motile Sperm</title>
          <description>Number of participants with undetectable or detectable sperm in their ejaculates.</description>
          <population>Men had idiopathic azoospermia, without evidence of obstruction or know genetic causes of azoospermia, although one man had known AZFc deletion</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>undetectable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>detectable motile sperm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Sperm and Percentage of These Sperm That Were Motile</title>
        <description>Number of total sperm in ejaculate and percentage of these sperm that were motile</description>
        <time_frame>32 weeks</time_frame>
        <population>Only man who developed sperm in ejaculate on treatment</population>
        <group_list>
          <group group_id="O1">
            <title>13-cis Retinoic Acid</title>
            <description>20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks&#xD;
13-cis retinoic acid: Accutane is used for the treatment of severe acne</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sperm and Percentage of These Sperm That Were Motile</title>
          <description>Number of total sperm in ejaculate and percentage of these sperm that were motile</description>
          <population>Only man who developed sperm in ejaculate on treatment</population>
          <units>Percent of sperm that were motile</units>
          <param>Number</param>
          <units_analyzed>Total sperm in the ejaculate</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total sperm in the ejaculate</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious and Non-Serious Adverse Effects</title>
        <description>Number of participants with Serious and Non-Serious Adverse effects associated with treatment with 13-cis retinoic acid</description>
        <time_frame>32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accutane-13-cis Retinoic Acid</title>
            <description>20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks&#xD;
13-cis retinoic acid: Accutane is used for the treatment of severe acne</description>
          </group>
        </group_list>
        <measure>
          <title>Serious and Non-Serious Adverse Effects</title>
          <description>Number of participants with Serious and Non-Serious Adverse effects associated with treatment with 13-cis retinoic acid</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>32 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Accutane-13-cis Retinoic Acid</title>
          <description>20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks&#xD;
13-cis retinoic acid: Accutane is used for the treatment of severe acne</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cramps</sub_title>
                <description>Muscle cramps</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Amory</name_or_title>
      <organization>University of Washington School of Medicine</organization>
      <phone>2066161727</phone>
      <email>jamory@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

